Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.

M. Özgüroğlu
  • Fonction : Auteur
N. Matsubara
  • Fonction : Auteur
N. Mehra
  • Fonction : Auteur
M. P. Kolinsky
  • Fonction : Auteur
G. Procopio
  • Fonction : Auteur
S. Feyerabend
  • Fonction : Auteur
J. Y. Joung
  • Fonction : Auteur
K. Nishimura
  • Fonction : Auteur
C. Gedye
  • Fonction : Auteur
C. Padua
  • Fonction : Auteur
N. Shore
  • Fonction : Auteur
F. Saad
  • Fonction : Auteur
R. van Alphen
  • Fonction : Auteur
M. A. Carducci
  • Fonction : Auteur
C. Desai
  • Fonction : Auteur
N. Brickel
  • Fonction : Auteur
C. Poehlein
  • Fonction : Auteur
P. del Rosario
  • Fonction : Auteur

Résumé

Background Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest. Methods Patients were randomized (2:1) to olaparib tablets (300 mg bid) or control (enzalutamide or abiraterone) until disease progression or unacceptable toxicity. Safety was assessed through AE reporting and laboratory assessments. Safety data were also collected from all patients in the control group who experienced radiographic disease progression and subsequently crossed over to olaparib treatment. Results 256 patients received olaparib and 130 control. Incidence rates for the four most commonly occurring AEs in the olaparib group (all-causality) were anaemia 50%, nausea 43%, fatigue/asthenia 42% and decreased appetite 31%. All were mostly Grade 1 and 2 and all peaked within the first 2 months of treatment as the events were managed where appropriate, primarily with dose interruptions or dose reductions. The extent of bone metastases at baseline or prior taxane use was not associated with the rate of anaemia. Pneumonitis was reported in 2% and 1.5% of patients in the olaparib and control groups, respectively, and one patient (0.4%) in the olaparib group experienced an event of MDS/AML after a 30-day follow-up period. Venous thromboembolic events occurred in 8% of olaparib and 3% of control patients. Conclusions The four most common AEs observed in PROfound were generally manageable without the need for treatment discontinuation, allowing patients to remain on treatment for as long as they were deriving clinical benefit.
Fichier principal
Vignette du fichier
PIIS0959804922002179.pdf (1.24 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04568938 , version 1 (06-05-2024)

Licence

Identifiants

Citer

Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More